The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J01 | Antibacterials for systemic use | |
| 3 | J01D | Other beta-lactam antibacterials | |
| 4 | J01DB | First-generation cephalosporins | |
| 5 | J01DB01 | Cefalexin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2 g |
| Active Ingredient | Description | |
|---|---|---|
| Cefalexin |
Cefalexin is an antibacterial agent of the cephalosporin class. Like other cephalosporins cefalexin exerts antibacterial activity by binding to and inhibiting the action of penicillin-binding proteins involved in the synthesis of bacterial cell walls. This leads to bacterial cell lysis and cell death. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| FELEXIN Hard capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| FELEXIN Powder for oral suspension | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| KEFLEX Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| MEDOLEXIN Capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| SYNTOLEXIN Capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
